AU2014211628B2 - Compositions comprising 15-OHEPA and methods of using the same - Google Patents

Compositions comprising 15-OHEPA and methods of using the same Download PDF

Info

Publication number
AU2014211628B2
AU2014211628B2 AU2014211628A AU2014211628A AU2014211628B2 AU 2014211628 B2 AU2014211628 B2 AU 2014211628B2 AU 2014211628 A AU2014211628 A AU 2014211628A AU 2014211628 A AU2014211628 A AU 2014211628A AU 2014211628 B2 AU2014211628 B2 AU 2014211628B2
Authority
AU
Australia
Prior art keywords
hepe
ohepa
subject
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014211628A
Other languages
English (en)
Other versions
AU2014211628A1 (en
Inventor
John Climax
Kevin Duffy
Jonathan Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of AU2014211628A1 publication Critical patent/AU2014211628A1/en
Assigned to AFIMMUNE LIMITED reassignment AFIMMUNE LIMITED Request for Assignment Assignors: DIGNITY SCIENCES LIMITED
Application granted granted Critical
Publication of AU2014211628B2 publication Critical patent/AU2014211628B2/en
Priority to AU2018206685A priority Critical patent/AU2018206685A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2014211628A 2013-01-30 2014-01-24 Compositions comprising 15-OHEPA and methods of using the same Ceased AU2014211628B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018206685A AU2018206685A1 (en) 2013-01-30 2018-07-16 Compositions Comprising 15-OHEPA And Methods Of Using The Same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
GBGB1301626.6 2013-01-30
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018206685A Division AU2018206685A1 (en) 2013-01-30 2018-07-16 Compositions Comprising 15-OHEPA And Methods Of Using The Same

Publications (2)

Publication Number Publication Date
AU2014211628A1 AU2014211628A1 (en) 2015-07-30
AU2014211628B2 true AU2014211628B2 (en) 2018-04-19

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014211628A Ceased AU2014211628B2 (en) 2013-01-30 2014-01-24 Compositions comprising 15-OHEPA and methods of using the same
AU2018206685A Abandoned AU2018206685A1 (en) 2013-01-30 2018-07-16 Compositions Comprising 15-OHEPA And Methods Of Using The Same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018206685A Abandoned AU2018206685A1 (en) 2013-01-30 2018-07-16 Compositions Comprising 15-OHEPA And Methods Of Using The Same

Country Status (27)

Country Link
US (6) US20150224076A1 (enExample)
EP (2) EP3058943B1 (enExample)
JP (2) JP6363104B2 (enExample)
KR (6) KR20240011872A (enExample)
CN (2) CN111214464A (enExample)
AU (2) AU2014211628B2 (enExample)
BR (1) BR112015018270A2 (enExample)
CA (1) CA2897343C (enExample)
CY (1) CY1117209T1 (enExample)
DK (1) DK2762143T3 (enExample)
ES (2) ES2759448T3 (enExample)
GB (1) GB201301626D0 (enExample)
HR (1) HRP20160203T1 (enExample)
HU (1) HUE026901T2 (enExample)
IL (3) IL239893A (enExample)
MX (2) MX364646B (enExample)
NZ (1) NZ709803A (enExample)
PH (1) PH12015501582B1 (enExample)
PL (1) PL2762143T3 (enExample)
PT (1) PT2762143E (enExample)
RS (1) RS54584B1 (enExample)
RU (2) RU2671208C2 (enExample)
SG (2) SG10201806854XA (enExample)
SI (1) SI2762143T1 (enExample)
SM (1) SMT201600069B (enExample)
WO (1) WO2014118097A1 (enExample)
ZA (2) ZA201505018B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2015071766A1 (en) 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
KR20160132372A (ko) * 2014-01-10 2016-11-18 디그너티 사이언스 리미티드 15-hepe를 포함하는 약제학적 조성물 및 이를 이용하는 천식 및 폐 장애의 치료 방법
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
CN117402059A (zh) * 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN108025181A (zh) 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017103671A1 (en) 2015-12-18 2017-06-22 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
EP0671901B1 (en) 1993-10-01 1998-01-14 R.P. Scherer Corporation Compositions for dispensing fragrances
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN1202068C (zh) 2000-02-16 2005-05-18 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
RU2003133142A (ru) 2001-05-30 2005-04-20 Лэксдейл Лимитед (GB) Коэнзим q и эйкозапентаеновая кислота (эпк)
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
ES2527438T3 (es) 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
ES2555782T3 (es) * 2007-03-30 2016-01-08 Kowa Company, Ltd. Fármaco para prevenir y/o tratar hígado graso o esteatosis hepática no alcohólica
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US8853437B2 (en) * 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP2768496A1 (en) 2011-10-19 2014-08-27 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2785852A4 (en) 2011-11-29 2015-11-04 Dignity Sciences Ltd COMPOSITIONS COMPRISING FATTY ACIDS CONTAINING CARBON ATOMS AND METHODS OF PREPARATION AND USE THEREOF
RU2664429C2 (ru) 2012-01-06 2018-08-17 Омтера Фармасьютикалс, Инк. Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
CA2873055C (en) * 2012-05-10 2023-10-10 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN108025181A (zh) * 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017103671A1 (en) 2015-12-18 2017-06-22 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. S. MASTERTON ET AL, "Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, (2010), vol. 31, no. 7, pages 679 - 692 *

Also Published As

Publication number Publication date
IL239893A (en) 2017-04-30
JP2016511753A (ja) 2016-04-21
IL265876A (en) 2019-06-30
US20220347147A1 (en) 2022-11-03
US20210228524A1 (en) 2021-07-29
EP3058943B1 (en) 2019-09-25
JP6363104B2 (ja) 2018-07-25
EP3058943A1 (en) 2016-08-24
RS54584B1 (sr) 2016-08-31
KR102514913B1 (ko) 2023-03-27
MX364646B (es) 2019-05-03
US10813903B2 (en) 2020-10-27
CY1117209T1 (el) 2017-04-05
EP2762143B1 (en) 2015-12-02
US20200069626A1 (en) 2020-03-05
CN105120872A (zh) 2015-12-02
GB201301626D0 (en) 2013-03-13
HUE026901T2 (en) 2016-07-28
CN111214464A (zh) 2020-06-02
IL239893A0 (en) 2015-08-31
KR20220119524A (ko) 2022-08-29
CN105120872B (zh) 2020-01-10
CA2897343C (en) 2021-03-16
SG11201505457PA (en) 2015-08-28
US20250186384A1 (en) 2025-06-12
KR20210088733A (ko) 2021-07-14
US20150224076A1 (en) 2015-08-13
KR20250105691A (ko) 2025-07-08
PL2762143T3 (pl) 2016-06-30
KR102434817B1 (ko) 2022-08-19
RU2671208C2 (ru) 2018-10-30
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
RU2015136849A (ru) 2017-03-06
SI2762143T1 (sl) 2016-04-29
CA2897343A1 (en) 2014-08-07
MX2015009803A (es) 2015-10-29
AU2014211628A1 (en) 2015-07-30
KR20150112995A (ko) 2015-10-07
KR102274963B1 (ko) 2021-07-08
ES2759448T3 (es) 2020-05-11
AU2018206685A1 (en) 2018-08-02
PT2762143E (pt) 2016-03-28
MX2019005082A (es) 2019-08-12
HRP20160203T1 (hr) 2016-03-25
KR20240011872A (ko) 2024-01-26
ES2564025T3 (es) 2016-03-17
BR112015018270A2 (pt) 2017-07-18
EP2762143A1 (en) 2014-08-06
DK2762143T3 (en) 2016-03-07
WO2014118097A1 (en) 2014-08-07
KR20230047201A (ko) 2023-04-06
PH12015501582A1 (en) 2015-10-05
IL251639A0 (en) 2017-06-29
ZA201605125B (en) 2018-06-27
US20210244697A1 (en) 2021-08-12
JP2018172409A (ja) 2018-11-08
SG10201806854XA (en) 2018-09-27
ZA201505018B (en) 2017-01-25
HK1200351A1 (en) 2015-08-07
NZ709803A (en) 2020-05-29
SMT201600069B (it) 2016-04-29

Similar Documents

Publication Publication Date Title
US20250186384A1 (en) Compositions comprising 15-ohepa and methods of using the same
AU2022291628B2 (en) Compositions comprising 15-HEPE and methods of using the same
EP3247348A1 (en) Compositions comprising 15-hepe and methods of using the same
HK1200351B (en) Compositions comprising 15-hepe and methods of using the same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AFIMMUNE LIMITED

Free format text: FORMER APPLICANT(S): DIGNITY SCIENCES LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired